DrugBank Interaction Checker Retiring March 2026: What Development Teams Should Evaluate Next

DrugBank has confirmed that its free, web-based Drug Interaction Checker will be retired on March 25, 2026. The tool, hosted at go.drugbank.com/drug-interaction-checker, allowed users to check interactions between up to five drugs at a time with limited result depth. DrugBank has stated that this change is part of a broader effort to refine its offering and focus resources on maintaining and expanding its core data products.

For teams that integrated workflow links to the free checker, or that used it during development as a quick reference, this retirement means those paths stop working in less than two weeks. DrugBank's commercial API and embeddable plugin remain available as paid products, but they represent a different cost and integration model than the free tool provided.

The timing is worth noting because this is the second significant drug interaction resource to be removed from public availability in the past two years. NLM discontinued the RxNav Drug Interaction API in January 2024. Teams that were already searching for replacements after that event now face another reduction in freely accessible interaction-checking tools.

Before selecting a replacement, it helps to clarify what role the DrugBank checker actually played in your workflow. There are several distinct use cases that often get conflated.

Some teams used the free checker as a lightweight development reference, verifying expected interaction pairs while building their own detection logic. Others linked to it from internal tools as a quick lookup resource for clinical or QA staff. A smaller set of teams may have been scraping or referencing results programmatically, though this fell outside DrugBank's terms of use.

Each of these cases leads to a different replacement strategy. If you need a curated, commercially licensed interaction database with severity scores and editorial oversight, DrugBank's own commercial API or alternatives like First Databank and Elsevier's Clinical Pharmacology exist in that space. If your requirement is actually about building interaction detection from authoritative public sources, the architecture looks different.

The FDA requires manufacturers to document known drug interactions in Section 7 of prescription drug labeling. This content is published in Structured Product Labeling (SPL) format and is accessible through two primary public channels: the openFDA drug label API and NLM's DailyMed service.

openFDA provides a searchable REST API over SPL-derived label data. The drug_interactions field contains the full text from Section 7 of the label. Related fields like warnings, contraindications, and boxed_warning often contain additional interaction-relevant safety information. Labels can be queried by RxCUI, NDC, generic name, or brand name, and the API supports filtering, sorting, and pagination.

DailyMed offers the same underlying SPL content through web services and downloadable data packages. Many teams use DailyMed for source fidelity and auditing workflows, since it provides direct access to the official label XML. For interaction detection specifically, openFDA's searchable field structure tends to reduce the amount of parsing required.

Neither source provides pre-structured, severity-scored interaction pairs out of the box. The label text is prose written by manufacturers under FDA review. Turning that prose into structured data is an engineering problem that requires natural language processing, and increasingly, large language models for extraction and classification.

Regardless of which evidence source you use, reliable drug name normalization is a prerequisite for any interaction detection system. Users submit drug names in inconsistent formats: brand names, generic names, abbreviations, misspellings, and NDC codes.

NLM's RxNorm API remains the standard public resource for resolving drug inputs to stable identifiers. The key endpoint for this is the RxCUI lookup, which supports exact, normalized, and approximate matching. Once you have an RxCUI, you can query openFDA labels reliably using the openfda.rxcui search field.

It is important to distinguish RxNorm's normalization capabilities (which remain active) from the discontinued RxNav Drug Interaction API (which was a separate service that returned pre-computed interaction pairs). The normalization layer is still available and remains essential for building any interaction pipeline against public data.

Teams replacing the DrugBank checker with a custom pipeline generally converge on a multi-stage architecture. The stages are intentionally separated to allow independent testing, caching, and failure handling.

The first stage is input normalization, where free-text drug inputs are resolved to canonical identifiers via RxNorm. The second stage is evidence retrieval, where label text is fetched from openFDA (or DailyMed) using those identifiers. The third stage is interaction extraction, where the prose text from drug_interactions and related label sections is parsed into structured interaction records. The fourth stage applies severity classification and recommendation logic. The final stage shapes the response into a contract-stable API format with source citations.

This separation matters because each stage has different failure modes, caching characteristics, and update frequencies. Labels update on a weekly cadence at most, so aggressive caching at the evidence layer is appropriate. Normalization results are even more stable. Extraction and classification logic, on the other hand, may evolve as your models improve.

One of the most challenging aspects of building an interaction detection system from label data is severity classification. Commercial databases like DrugBank provide editorially curated severity levels. When working from raw label text, you need a classification strategy.

FDA label language provides strong signals for severity. Boxed warnings and contraindications indicate the highest severity. Phrases like 'concomitant use is contraindicated' or 'do not use together' map clearly to a contraindicated classification. The drug_interactions section uses language patterns that often distinguish between interactions requiring dose adjustment, monitoring, or avoidance.

A practical approach is to define a severity scale (such as contraindicated, major, moderate, minor, and unknown) and map label language patterns to those levels using a combination of deterministic keyword analysis and LLM-based classification. The deterministic layer catches clear-cut cases; the LLM handles nuanced prose where severity must be inferred from context. Both layers should retain the source text snippet as evidence, so downstream consumers can verify the classification.

Any system that surfaces drug interaction information to clinicians or patients should include traceable evidence citations. This is both a regulatory consideration and a trust-building measure for API consumers.

At minimum, each interaction result should reference the source label's SPL Set ID (the stable identifier for a drug's labeling across versions), the specific label section from which the interaction was extracted (for example, drug_interactions or contraindications), and the effective date of the label. This allows downstream systems to link back to the authoritative source on DailyMed or FDA.gov.

Teams building for regulated environments often need to go further, retaining the exact text snippet that was used for extraction and classification, along with metadata about the extraction method and confidence level. This creates an audit trail that supports clinical review and quality assurance workflows.

If you are migrating from DrugBank's interaction checker to a label-based pipeline, expect differences in coverage and granularity. DrugBank's curated database includes interaction pairs that may not have explicit mentions in FDA labeling, particularly for interactions derived from pharmacokinetic studies or post-market reports that have not yet been incorporated into product labels.

A practical migration strategy is to build a reconciliation set: take your most critical interaction pairs (the ones your users depend on), run them through your new pipeline, and compare results against your DrugBank baseline. Document gaps and decide how to handle them. Some gaps may be acceptable; others may require supplementary data sources.

Testing should cover not just correctness of known pairs, but also behavior on edge cases: misspelled drug names, combination products, drugs with multiple brand names, and inputs that resolve to multiple RxCUIs. The normalization layer is often where the most subtle bugs appear.

RxLabelGuard is one implementation of the architecture pattern described above. It provides a managed API that handles drug name normalization via RxNorm, label retrieval from openFDA, interaction extraction using a combination of deterministic analysis and LLM-based structuring via AWS Bedrock, and severity classification with evidence citations traced back to source labels.

It does not replace a curated commercial database like DrugBank's full dataset. What it provides is a pipeline built on publicly available FDA label data, with structured output and source traceability, delivered as an API that development teams can integrate without building and maintaining the extraction infrastructure themselves.

For teams evaluating their options after the DrugBank checker retirement, the choice depends on your specific requirements: coverage breadth, severity curation methodology, regulatory environment, budget, and integration timeline. We encourage evaluating multiple options, including commercial databases, before making a decision.

The March 25, 2026 retirement date is firm, so teams that depend on the DrugBank checker should begin their evaluation now. Start by documenting your current usage patterns and requirements. Determine whether you need a curated commercial database, a label-evidence pipeline, or some combination of both.

If your path leads toward public label data, invest time in understanding the openFDA drug label API and RxNorm's normalization endpoints. These are the foundational building blocks for any label-based interaction detection system. The learning curve is manageable, but the nuances of drug name resolution and label text extraction benefit from early experimentation.